Submitted for Publication: June 14, 2013; final revision received November 11, 2013; accepted December 9, 2013.
Published Online: February 20, 2014. doi:10.1001/jamaophthalmol.2013.7995.
Study concept and design: Moss, Balcer, Joslin.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Moss.
Critical revision of the manuscript for important intellectual content: All authors.
Conflict of Interest Disclosures: Dr Balcer has received consulting fees and speaking honoraria for work to develop visual function and optical coherence tomography outcomes for multiple sclerosis trials from Biogen-Idec, Questcor, and Accorda. No other disclosures were reported.
Funding/Support: This study was supported by an unrestricted departmental grant from Research to Prevent Blindness (Drs Moss and Joslin) and by grants K12EY02147 (Dr Moss), UL1TR000050 and P60MD003424 (Dr Joslin), and P60MD003424-02S1 (Dr Joslin) from the National Institutes of Health.
Role of the Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Previous Presentation: A preliminary version of this analysis was presented at the 39th Annual North American Neuro-Ophthalmology Society Annual Meeting; February 12, 2013; Snowbird, Utah.